The mechanisms of positive effects of melatonin in dyslipidemia: A systematic review of animal and human studies

International Journal of Pharmacology

Volumn 8, Issue 6, 2012, Pages 496-509

  Mozaffari, Shilan ^a   Hasani Ranjbar, Shirin ^b   Abdollahi, Mohammad ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Dyslipidemia; Lipid peroxidation; Low density lipoprotein; Melatonin; Pro inflammatory cytokines

Indexed keywords

ADIPONECTIN; ALPHA TOCOPHEROL; ASCORBIC ACID; CHOLESTEROL; COPPER ZINC SUPEROXIDE DISMUTASE; FREE RADICAL; GLUTATHIONE; INSULIN; INTERLEUKIN 1; LEPTIN; LIPID; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; MELATONIN; MITOGEN ACTIVATED PROTEIN KINASE; MYOSIN LIGHT CHAIN KINASE; PIOGLITAZONE; PLACEBO; PROTEIN KINASE C; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CYTOKINE RELEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DYSLIPIDEMIA; ELECTRON TRANSPORT; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; INHIBITION KINETICS; LIPID BLOOD LEVEL; LIPID PEROXIDATION; LIVER INJURY; METABOLIC SYNDROME X; MONOCYTE; NONALCOHOLIC FATTY LIVER; NONHUMAN; RADIATION PROTECTION; RESPIRATORY CHAIN; SYSTEMATIC REVIEW;

EID: 84866137495     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2012.496.509     Document Type: Article

References (85)

1. Abdel-Wahab, M.H. and A.R.A. Abd-Allah, 2000. Possible protective effect of melatonin and/or desferrioxamine against streptozotocin-induced hyperglycaemia in mice. Pharmacol. Res., 41: 533-537.
2. Abdollahi, M., A. Ranjbar, S. Shadnia, S. Nikfar and A. Rezaie, 2004. Pesticides and oxidative stress: A review. Med. Sci. Monit., 10: RA141-RA147.
3. Abuja, P.M., P. Liebmann, M. Hayn, K. Schauenstein and H. Esterbauer, 1997. Antioxidant role of melatonin in lipid peroxidation of human LDL. FEBS Lett., 413: 289-293.
4. Agil, A., M. Navarro-Alarcon, R. Ruiz, S. Abuhamadah, M.Y. El-Mir and G.F. Vazquez, 2011. Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats. J. Pineal Res., 20: 207-212.
5. Ahlers, I., P. Solar, E. Ahlersova, M. Kassayova and B. Smajda, 1997. The influence of melatonin on metabolic changes in female rats induced by continuous irradiation and/or administration of 7,12-dimethylbenz/a/anthracene. Neoplasma, 44: 253-257.
6. Ahmed, H.H., F. Mannaa, G.A. Elmegeed and S.H. Doss, 2005. Cardioprotective activity of melatonin and its novel synthesized derivatives on doxorubicin-induced cardiotoxicity. Bioorg. Med. Chem., 3: 1847-1857.
7. Aoyama, H., N. Mori and W. Mori, 1988. Effects of melatonin on genetic hypercholesterolemia in rats. Atherosclerosis, 69: 269-272.
8. Baydas, G., H. Canatan and A. Turkoglu, 2002. Comparative analysis of the protective effects of melatonin and vitamin E on streptozocin induced diabetes mellitus. J. Pineal Res., 32: 225-230.
9. Bhattacharyya, S., J. Luan, B. Challis, J. Keogh and C. Montague et al., 2006. Sequence variants in the melatonin-related receptor gene (GPR50) associate with circulating triglyceride and HDL levels. J. Lipid Res., 47: 761-766.
10. Bojkova, B., P. Orendas, L. Friedmanova, M. Kassayova, I. Datelinka, E. Ahlersova and I. Ahlers, 2008. Prolonged melatonin administration in 6-month-old Sprague-Dawley rats: Metabolic alterations. Acta Physiol. Hung., 95: 65-76.
11. Bonnefont-Rousselot, D., G. Cheve, A. Gozzo, A. Tailleux and V. Guilloz et al., 2002. Melatonin related compounds inhibit lipid peroxidation during copper or free radical-induced LDL oxidation. J. Pineal Res., 33: 109-117.
12. Bonnefont-Rousselot, D., V. Guilloz, S. Lepage, C. Bizard and P. Duriez et al., 2003. Protection of endogenous beta-carotene in LDL oxidized by oxygen free radicals in the presence of supraphysiological concentrations of melatonin. Redox. Rep., 8: 95-104.
13. Broncel, M., M. Kozirog-Kolacinska and J. Chojnowska-Jezierska, 2007. Melatonin in the treatment of atherosclerosis. Pol. Merkur. Lekarski., 23: 124-127.
14. Chan, T.Y. and P.L. Tang, 1995. Effect of melatonin on the maintenance of cholesterol homeostasis in the rat. Endocr. Res., 21: 681-696.
15. Damian, E., O. Ianas and I. Badescu, 1988. Decrease in high-density lipoprotein cholesterol after administration of melatonin-free pineal extract in the rat. Endocrinologie, 26: 17-20.
16. Daniels, W.M., R.J. Reiter, D. Melchiorri, E. Sewerynek, M.I. Pablos and G.G. Ortiz, 1995. Melatonin counteracts lipid peroxidation induced by carbon tetrachloride but does not restore glucose-6 phosphatase activity. J. Pineal Res., 19: 1-6.
17. Dominguez-Rodriguez, A., P. Abreu-Gonzalez, M. Garcia-Gonzalez, J. Ferrer-Hita, M. Vargas and R.J. Reiter, 2005. Elevated levels of oxidized low-density lipoprotein and impaired nocturnal synthesis of melatonin in patients with myocardial infarction. Atherosclerosis, 180: 101-105.
18. El-Missiery, M.A., T.A. Fayed, M.R. El-Sawy and A.A. El-Sayed, 2007. Ameliorative effect of melatonin against gamma-irradiation-induced oxidative stress and tissue injury. Ecotoxicol. Environ. Saf., 66: 278-286.
19. Esquifino, A., C. Agrasal, E. Velazquez, M.A. Villanua and D.P. Cardinali, 1997. 1997 Effect of melatonin on serum cholesterol and phospholipid levels, and on prolactin, thyroid-stimulating hormone and thyroid hormone levels, in hyperprolactinemic rats. Life Sci., 61: 1051-1058.
20. Garfinkel, D., M. Zorin, J. Wainstein, Z. Matas, M. Laudon and N. Zisapel, 2011. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: A randomized, double-blind, crossover study. Diabetes Metab. Syndr. Obes., 42: 307-313.
21. Gitto, E., S. Pellegrino, P. Gitto, I. Barberi and R.J. Reiter, 2009. Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin. J. Pineal Res., 46: 128-139.
22. Gonciarz, M., Z. Gonciarz, W. Bielanski, A. Mularczyk, P.C. Konturek and T. Brzozowski, 2010. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: Effect on plasma levels of liver enzymes, lipids and melatonin. J. Physiol. Pharmacol., 61: 705-710.
23. Hadjibabaie, M., K. Gholami, H. Khalili, S.H. Khoei and M. Nakhjavani et al., 2006. Comparative efficacy and safety of atorvastatin, simvastatin, and lovastatin in the management of dyslipidemic type 2 diabetic patients. Therapy, 3: 759-764.
24. Hadjibabaie, M., S. Vosough-Ghanbari, M. Radfar, K. Gholami and S.H. Khoei et al., 2007. Comparative efficacy of daily versus alternate-day dosing of atorvastatin in type 2 diabetic patients. Therapy, 4: 541-545.
25. Hasani-Ranjbar, S., B. Larijani and M. Abdollahi, 2009. A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflamm. Allergy Drug Targets, 8: 2-10.
26. Hasani-Ranjbar, S., B. Larijani and M. Abdollahi, 2011. Recent update on animal and human evidences of promising antidiabetic medicinal plants: A mini-review of targeting new drugs. Asian J. Anim. Vet. Adv., 6: 1271-1275.
27. Hasani-Ranjbar, S., N. Nayebi, L. Moradi, A. Mehri, B. Larijani and M. Abdollahi, 2010. The efficacy and safety of herbal medicines used in the treatment of hyperlipidemia: A systematic review. Curr. Pharm. Des., 16: 2935-2947.
28. Hasani-Ranjbar, S., S. Khosravi, N. Nayebi, B. Larijani and M. Abdollahi, 2012. Systematic review of the efficacy and safety of anti-aging herbs in animals and human. Asian J. Anim. Vet. Adv., 7: 621-640.
29. Hoyos, M., J.M. Guerrero, R.P. Cano, J. Olivan, F. Fabiani, A.G. Perganeda and C. Osuna, 2000. Serum cholesterol and lipid peroxidation are decreased by melatonin in diet induced hypercholesterolemic rats. J. Pineal Res., 28: 150-155.
30. Kadhim, H.M., S.H. Ismail, K.I. Hussein, I.H. Bakir, A.S. Sahib, B.H. Khalaf and S.A. Hussain, 2006. Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin. J. Pineal Res., 41: 189-193.
31. Kelly, M.R. and G. Loo, 1997. Melatonin inhibits oxidative modification of human low-density lipoprotein. J. Pineal Res., 22: 203-209.
32. Korkmaz, A., D.X. Tan and J.R. Russel, 2011. Melatonin: An established radioprotective agent against Japan's nuclear disaster. TAF Prevent. Med. Bull., 10: 127-129.
33. Korkmaz, A., T. Topal, D.X. Tan and R.J. Reiter, 2009. Role of melatonin in metabolic regulation. Rev. Endocr. Metab. Disord., 100: 261-270.
34. Kozel'tsev, V.L., T.V. Volodina, V.V. Guseva and N.V. Kostiuk, 2007. Changes in lipids of granulation fibrous tissue in rats at various doses and routes of melatonin administration. Biomed. Khim., 53: 50-56.
35. Kozirog, M., A.R. Poliwczak, P. Duchnowicz, M. Koter-Michalak, J. Sikora and M. Broncel, 2011. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J. Pineal Res., 50: 261-266.
36. Malekirad, A.A., M. Mojtabaee, M. Faghih, G. Vaezi and M. Abdollahi, 2012. Effects of the mixture of Melissa officinalis L., Cinnamomum zeylanicum and Urtica dioica on hepatic enzymes activity in patients with nonalcoholic fatty liver disease. Int. J. Pharmacol., 8: 204-208.
37. Malekirad, A.A., N. Hosseini, M. Bayrami, T. Hashemi, K. Rahzani and M. Abdollahi, 2011. Benefit of lemon verbena in healthy subjects, targeting diseases associated with oxidative stress. Asian J. Anim. Vet. Adv., 6: 953-957.
38. Marchetti, C., N. Sidahmed-Adrar, F. Collin, D. Jore, M. Gardes-Albert and D. Bonnefont-Rousselot, 2011. Melatonin protects PLPC liposomes and LDL towards radical-induced oxidation. J. Pineal Res., 51: 286-296.
39. Mehri, A., S. Hasani-Ranjbar, B. Larijani and M. Abdollahi, 2011. A systematic review of efficacy and safety of Urtica dioica in the treatment of diabetes. Int. J. Pharmacol., 7: 161-170.
40. Mekhloufi, J., H. Vitrac, S. Yous, P. Duriez, D. Jore, M. Gardes-Albert and D. Bonnefont-Rousselot, 2007. Quantification of the water/lipid affinity of melatonin and a pinoline derivative in lipid models. J. Pineal Res., 42: 330-337.
41. Mohammadirad, A., H.R. Khorram-Khorshid, F. Gharibdoost and M. Abdollahi, 2011. Setarud (IMODTM) as a multiherbal drug with promising benefits in animal and human studies: A comprehensive review of biochemical and cellular evidences. Asian J. Anim. Vet. Adv., 6: 1185-1192.
42. Momtaz, S. and M. Abdollahi, 2010. An update on pharmacology of Satureja species: From antioxidant, antimicrobial, antidiabetes and anti-hyperlipidemic to reproductive stimulation. Int. J. Pharmacol., 6: 346-353.
43. Momtaz, S. and M. Abdollahi, 2012. A comprehensive review of biochemical and molecular evidences from animal and human studies on the role of oxidative stress in aging: An Epiphenomenon or the Cause. Asian. J. Anim. Vet. Adv. 7: 1-19.
44. Montilla, P.L., I.F. Tunez, C. Munoz de Agueda, F.L. Gascon and J.V. Soria, 1998. Protective role of melatonin and retinol palmitate in oxidative stress and hyperlipidemic nephropathy induced by adriamycin in rats. J. Pineal Res., 25: 86-93.
45. Montilla, P.L., J.F. Vargas, I.F. Tunez, M.C. Munoz de Agueda, M.E. Valdelvira and E.S Cabrera, 1998. Oxidative stress in diabetic rats induced by streptozotocin: Protective effects of melatonin. J. Pineal Res., 25: 94-100.
46. Morgan, L., J. Arendt, D. Owens, S. Folkard, S. Hampton and S. Deacon, 1998. Effects of the endogenous clock and sleep time on melatonin, insulin, glucose and lipid metabolism. J. Endocrinol., 157: 443-451.
47. Mori, N., H. Aoyama, T. Murase and W. Mori, 1989. Anti-hypercholesterolemic effect of melatonin in rats. Acta Pathol. Jpn., 39: 613-618.
48. Morrey, K.M., J.A. McLachlan, C.D. Serkin and O. Bakouche, 1994. Activation of human monocytes by the pineal hormone melatonin. J. Immunol., 153: 2671-2680.
49. Mozaffari, S. and M. Abdollahi, 2011. Melatonin, a promising supplement in inflammatory bowel disease: A comprehensive review of evidences. Curr. Pharm. Des., 17: 4372-4378.
50. Muller-Wieland, D., B. Behnke, K. Koopmann and W. Krone, 1994. Melatonin inhibits LDL receptor activity and cholesterol synthesis in freshly isolated human mononuclear leukocytes. Biochem. Biophys. Res. Commun., 203: 416-421.
51. Nishida, S., 2005. Metabolic effects of melatonin on oxidative stress and diabetes mellitus. Endocrine, 27: 131-136.
52. Nishida, S., R. Sato, I. Murai and S. Nakagawa, 2003. Effect of pinealectomy on plasma levels of insulin and leptin and on hepatic lipids in type 2 diabetic rats. J. Pineal Res., 35: 251-256.
53. Nishida, S., T. Segawa, I. Murai and S. Nakagawa, 2002. Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Delta-5 desaturase activity. J. Pineal Res., 32: 26-33.
54. Ohta, Y., M. Kongo, E. Sasaki, K. Nishida and I. Ishiguro, 2000. Therapeutic effect of melatonin on carbon tetrachloride-induced acute liver injury in rats. J. Pineal Res., 28: 119-126.
55. Okatani, Y., A. Wakatsuki, K. Watanabe, K. Taniguchi and T. Fukaya, 2000. Melatonin suppresses lysophosphatidylcholine enhancement of serotonin-induced vasoconstriction in the human umbilical artery. J. Pineal Res., 29: 241-247.
56. Okatani, Y., A. Wakatsuki, K. Watanabe, N. Ikenoue and T. Fukaya, 2000. Melatonin inhibits vasospastic action of oxidized low-density lipoprotein in human umbilical arteries. J. Pineal Res., 29: 74-80.
57. Patel, V., A. Upaganlawar, R. Zalawadia and R. Balaraman, 2010. Cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats: A biochemical, electrocardiographic and histoarchitectural evaluation. Eur. J. Pharmacol., 644: 160-168.
58. Pieri, C., M. Marra, R. Gaspar and S. Damjanovich, 1996. Melatonin protects LDL from oxidation but does not prevent the apolipoprotein derivatization. Biochem. Biophys. Res. Commun., 222: 256-260.
59. Prunet-Marcassus, B., M. Desbazeille, A. Bros, K. Louche and P. Delagrange et al., 2003. Melatonin reduces body weight gain in Sprague dawley rats with diet-induced obesity. Endocrinology, 144: 5347-5352.
60. Rahimi, H.R., M. Gholami, H.R. Khorram-Khorshid, F. Gharibdoost and M. Abdollahi, 2012. On the protective effects of IMOD and silymarin combination in a rat model of acute hepatic failure through anti oxidative stress mechanisms. Asian. J. Anim. Vet. Adv., 7: 38-45.
61. Rahimi, R., S. Nikfar, B. Larijani and M. Abdollahi, 2005. A review on the role of antioxidants in the management of diabetes and its complications. Biomed. Pharmacother., 59: 365-373.
62. Rindone, J.P. and R. Achacoso, 1997. Effect of melatonin on serum lipids in patients with hypercholesterolemia: A pilot study. Am. J. Ther., 4: 409-411.
63. Rios-Lugo, M.J., P. Cano, V. Jimenez-Ortega, M.P. Fernandez-Mateos, P.A. Scacchi, D.P. Cardinali and A.I. Esquifino, 2010. Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high fat-fed rats. J. Pineal Res., 49: 342-348.
64. Sanchez-Mateos, S., C. Alonso-Gonzalez, A. Gonzalez, C.M. Martinez-Campa, M.D. Mediavilla, S. Cos and E.J. Sanchez-Barcelo, 2007. Melatonin and estradiol effects on food intake, body weight and leptin in ovariectomized rats. Maturitas, 58: 91-101.
65. Sandyk, R. and G.I. Awerbuch, 1994. The relationship between melatonin secretion and serum cholesterol in patients with multiple sclerosis. Int. J. Neurosci., 76: 81-86.
66. Sarwar, M., I.H. Attitalla and M. Abdollahi, 2011. A review on the recent advances in pharmacological studies on medicinal plants: Animal studies are done but clinical studies needs completing. Asian J. Anim. Vet. Adv., 6: 867-883.
67. Seabra, M.L., M. Bignotto, L.R. Pinto and S. Tufik, 2000. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J. Pineal Res., 29: 193-200.
68. Seegar, H., A.O. Mueck and T.H. Lippert, 1997. Effect of melatonin and metabolites on copper-mediated oxidation of flow density lipoprotein. Br. J. Clin. Pharmacol., 44: 283-284.
69. Sener, A., D. Ozsavci, O. Bingol-Ozakpinar, O. Cevik, G. Yanikkaya-Demirel and T. Yardimci, 2009. Oxidized-LDL and Fe3+/ascorbic acid-induced oxidative modifications and phosphatidylserine exposure in human platelets are reduced by melatonin. Folia Biol. (Praha), 55: 45-52.
70. Sener, G., J. Balkan, U. Cevikbas, M. Keyer-Uysal and M. Uysal, 2004. Melatonin reduces cholesterol accumulation and prooxidant state induced by high cholesterol diet in the plasma, the liver and probably in the aorta of C57BL/6J mice. J. Pineal Res., 36: 212-216.
71. Sewerynek, E., 2002. Melatonin and the cardiovascular system. Neuro. Endocrinol. Lett., 23: 79-83.
72. Sewerynek, E., D. Melchiorri, L. Chen and R.J. Reiter, 1995. Melatonin reduces both basal and bacterial lipopolysaccharide-induced lipid peroxidation in vitro. Free Radic. Biol. Med., 19: 903-909.
73. She, M., X. Deng, Z. Guo, M. Laudon and Z. Hu et al., 2009. NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats. Pharmacol. Res., 59: 248-253.
74. Subramanian, P., S. Mirunalini, S.R. Pandi-Perumal, I. Trakht and D.P. Cardinali, 2007. Melatonin treatment improves the antioxidant status and decreases lipid content in brain and liver of rats. Eur. J. Pharmacol., 71: 116-119.
75. Tailleux, A., G. Torpier, D. Bonnefont-Rousselot, S. Lestavel and M. Lemdani et al., 2002. Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta. Biochem. Biophys. Res. Commun., 293: 1114-1123.
76. Tamura, H., Y. Nakamura, A. Narimatsu, Y. Yamagata, A. Takasaki, R.J. Reiter and N. Sugino, 2008. Melatonin treatment in peri- and postmenopausal women elevates serum high-density lipoprotein cholesterol levels without influencing total cholesterol levels. J. Pineal Res., 45: 101-105.
77. Tan, D.X., R.J. Reiter, L.C. Manchester, M.T. Yan and M. El-Sawi et al., 2002. Chemical and physical properties and potential mechanisms: Melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem., 2: 181-197.
78. Vijayasarathy, K., K.S. Naidu and B.K.S. Sastry, 2010. Melatonin metabolite 6-Sulfatoxymelatonin, Cu/Zn superoxide dismutase, oxidized LDL and malondialdehyde in unstable angina. Int. J. Cardiol., 144: 315-317.
79. Vlachou, M., A. Eikosipentaki and V. Xenogiorgis, 2006. Pineal hormone melatonin: Solubilization studies in model aqueous gastrointestinal environments. Curr. Drug Deliv., 3: 255-265.
80. Wakatsuki, A., Y. Okatani Y N. Ikenoue, C. Izumiya and C. Kaneda, 2000. Melatonin inhibits oxidative modification of low-density lipoprotein particles in normolipidemic post-menopausal women. J. Pineal Res., 28: 136-142.
81. Wakatsuki, A., Y. Okatani, N. Ikenoue, K. Shinohara, K. Watanabe and T. Fukaya, 2001. Melatonin protects against oxidized low-density lipoprotein-induced inhibition of nitric oxide production in human umbilical artery. J. Pineal. Res., 31: 281-288.
82. Walters-Laporte, E., C. Furman, S. Fouquet, F. Martin-Nizard and S. Lestave et al., 1998. A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cells. J. Cardiovasc. Pharmacol., 32: 582-592.
83. Wang, H.X., F. Liu and T.B. Ng, 2001. Examination of pineal indoles and 6-methoxy-2-benzoxazolinone for antioxidant and antimicrobial effects. Comp. Biochem. Physiol. C Toxicol. Pharmacol., 130: 379-388.
84. Zaitone, S., N. Hassan, N. El-Orabi and El-S. El-Awady, 2011. Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease. Eur. J. Pharmacol., 662: 70-77.
85. Zhu, H.Q., X.W. Cheng, L.L. Xiao, Z.K. Jiang and Q. Zhou et al., 2008. Melatonin prevents oxidized low-density lipoprotein-induced increase of myosin light chain kinase activation and expression in HUVEC through ERK/MAPK signal transduction. J. Pineal Res., 45: 328-334.